Editing Management of HIV/AIDS (section)

===Integrase inhibitors===
[[Integrase inhibitor]]s (also known as integrase nuclear strand transfer inhibitors or INSTIs) inhibit the viral enzyme [[integrase]], which is responsible for [[retroviral integration|integration]] of viral DNA into the DNA of the infected cell. There are several integrase inhibitors under clinical trial,{{when|date=January 2021}} and [[raltegravir]] became the first to receive FDA approval in October 2007. Raltegravir has two metal binding groups that compete for substrate with two Mg<sup>2+</sup> ions at the metal binding site of integrase. As of early 2022, four other clinically approved integrase inhibitors are [[elvitegravir]], [[dolutegravir]], [[bictegravir]], and [[cabotegravir]].<ref>{{cite book | vauthors = Métifiot M, Marchand C, Pommier Y | chapter = HIV integrase inhibitors: 20-year landmark and challenges  | volume = 67 | pages = 75–105 | year = 2013 | pmid = 23885999 | doi = 10.1016/B978-0-12-405880-4.00003-2 | isbn = 9780124058804 | series = Advances in Pharmacology | title = Antiviral Agents | pmc = 7569752 | chapter-url = https://zenodo.org/record/1258666 }}</ref>